| Pharmaceutical Information |
| Drug Name |
Raxibacumab |
| Drug ID |
BADD_D01918 |
| Description |
Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012. |
| Indications and Usage |
Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. |
| Marketing Status |
approved |
| ATC Code |
J06BC02 |
| DrugBank ID |
DB08902
|
| KEGG ID |
D05706
|
| MeSH ID |
C542124
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
71655-103; 49401-080 |
| UNII |
794PGL549S
|
| Synonyms |
raxibacumab | raxibacumab monoclonal antibody, human | abthrax |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
565451-13-0 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
